Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
71.4M
-
Number of holders
-
121
-
Total 13F shares, excl. options
-
64.2M
-
Shares change
-
+3.08M
-
Total reported value, excl. options
-
$366M
-
Value change
-
+$21.1M
-
Put/Call ratio
-
0.08
-
Number of buys
-
66
-
Number of sells
-
-56
-
Price
-
$5.70
Significant Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) as of Q3 2024
156 filings reported holding CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2024.
C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) has 121 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64.2M shares
of 71.4M outstanding shares and own 89.93% of the company stock.
Largest 10 shareholders include Lynx1 Capital Management LP (6.88M shares), Soleus Capital Management, L.P. (6.6M shares), WASATCH ADVISORS LP (5.68M shares), BlackRock, Inc. (4.89M shares), RA CAPITAL MANAGEMENT, L.P. (4.88M shares), ORBIMED ADVISORS LLC (4.38M shares), COMMODORE CAPITAL LP (3.41M shares), VANGUARD GROUP INC (3.37M shares), STATE STREET CORP (2.81M shares), and MORGAN STANLEY (2.33M shares).
This table shows the top 121 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.